Galina Dmitrievna G., 61 years old, suffers from Anaplastic glioma.
In 2012, she was diagnosed with a tumor completely by chance. I went on vacation to Korea, where they placed us in a medical facility for examination. According to the results of the scan, a neoplasm was found in the brain, and the doctors recommended that I fly to Russia for treatment or have surgery with them. I decided to stay in the Korean hospital where I had trepanation and the tumor was removed. Histology showed that the neoplasm was benign, and I calmly returned home.
But since then, he has periodically traveled from Kamchatka to St. He began to fly to St. Petersburg. Apparently, such vigilance was justified: seven years after the operation, in 2019, a doctor from Academician Pavlov Medical University conducted an MRI and, analyzing the results of the study, saw the growth of the neoplasm. He offered thermal destruction of the tumor and helped me with quota registration. The new histology showed that the pathology in the brain was unfortunately malignant.
Radiation therapy was supposed to be the next step and I was recommended to apply it at the Medical Institute in Pesochny. Berezina Sergey (MIBS) as an institution with the most modern technology. I went to the reception - I liked it, realized that I was in good hands. Radiation course completed on the TrueBeam device.
After the protocol, a long-term drug treatment would begin. The doctors didn't insist on getting chemo in MIBS, they told me to turn to someone I could trust. I've been looking for "my" oncologist for a long time. I went around many clinics, shed tears of desperation: a specialist as sensitive as a digger is needed here, they are not kidding with the brain. I've been to many doctors, but I didn't feel like this was what I was looking for.
Finally, at the beginning of 2020, a patient friend from Murmansk advised me to find Mikhail Yuryevich Anishkin. And - what a coincidence! - He also worked in MIBS. Before the appointment, they took all the tests and medical documents from me and delivered them to the doctor. Mikhail Yuryevich got acquainted with my story and I was taken to him for consultation. I was very worried, but Mikhail Yuryevich made the best impression. When you communicate with him, you immediately understand that he is a very competent doctor and a very caring, attentive person. He speaks like a colleague (of course in the language I understand), always explaining in detail what he is doing and how he changes the appointment.
Mikhail Yuryevich prescribed temozolomide for me, already 18 cycles have been completed. To first set up her appointment every two months, St. Petersburg, then quarterly, now the frequency has dropped to once every six months. The doctor always carefully asked what hurts, what worries, and based on this, he chose the dosage of drugs. And it helped so subtly that there were no "side effects" (nausea).
I also want to note the quality of the medical reports and advice that Mikhail Yuryevich gave to the doctors at my place of residence: they are so detailed and complete that no questions are asked.
Two years passed, my condition stabilized, now there is no cure. But Mikhail Yuryevich suggested that in six months do an MRI and sign up for a consultation with him. And I will definitely heed my doctor's advice!
Oncologist, head of the outpatient oncology department Mikhail Yuryevich Anishkin Head of the Department of Outpatient Oncology at MIBS Mikhail Yurievich Anishkin Galina Dmitrievna, in the spring of 2020, requested a consultation in the spring of COVID-19, which should solve two critical questions: revealed in the latest MRI of the brain What should be done with the new pathological contrast focus (and for how long should Temozolomide therapy (if any) be continued after radiation therapy for anaplastic glioma recurrence?
How to distinguish post-radiation changes in the brain from a new tumor scan is one of the most difficult problems in neurooncology. Often times a clear answer in the here and now is simply impossible. To resolve this issue, two teams of MIBS radiologists, MRI and PET-CT specialists, would need to work together in the coming months. The primary interpretation of the situation was correct, not in favor of drop-outs, as time has shown.
Considering the preliminary results of the key multicenter international study from CATNON, published in the fall of 2017, which demonstrated the benefits of long-term maintenance chemotherapy for patients with anaplastic glioma, the patient was advised to continue treatment. Currently, Galina Dmitrievna is observed in our center, and control examinations are carried out several times a year.